Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 23;10(1):21.
doi: 10.1186/s40413-017-0150-7. eCollection 2017.

Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador

Affiliations

Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador

A Cherrez et al. World Allergy Organ J. .

Abstract

Background: The current EAACI/GA2LEN/EDF/WAO guideline for urticaria provide specific recommendations for the diagnostic workup and treatment of patients with chronic spontaneous urticaria (CsU). This study explored if physicians in Ecuador know these recommendations and implement them in their actual clinical practice for CsU.

Methods: We investigated physicians who treat CsU patients in a cross-sectional study using a standardized questionnaire. Descriptive statistics were employed, adjusted logistic regression was performed to assess the link of guideline knowledge and use of therapy.

Results: Seven hundred forty surveys were collected and analyzed. The mean age of physicians was 42.3 (±12.5) years. Most of the participants (65.1%) were general physicians (GP), 13.7% were pediatricians, 11.0% internists, 6.8% dermatologists or allergists (D/A). Only 18.8% knew the EAACI/GA2LEN/EDF/WAO guideline. 44.5% of GPs searched for CsU etiology in contrast to 90% of D/A. Most common diagnostic test was total serum IgE (83.5%). Most common first line symptomatic treatment was oral corticoids (46.3%), followed by second generation antihistamines (sgAHs, 36.8%). A/D prescribed more sgAHs (regular doses) (74.1 vs 28.6% of GP) (p < 0.05). Experience with omalizumab was reported only by 3.5%, of physicians, and higher rates among who were familiar with the guideline.

Conclusion: This study shows that the knowledge of guideline recommendations in physicians who treat urticaria patients in Ecuador is low. The diagnostic workup and treatment of CsU patients are largely not in line with guideline recommendations in real life practice settings. We were able to compare results between German and Ecuadorian physicians and found that Ecuadorian physicians have lower awareness of the current guideline (33 vs 18%). Only one-third of physicians reported using regular doses of sgAHs as the first line treatment. Also, only 12.9% of physicians use sgAHs in higher doses and physicians still use fgAHs, particularly pediatricians (42.9%). Our results suggest that disparities in knowledge between physicians from different countries could influence the management of CsU. Knowledge of the guidelines is linked to better choices of treatments. Awareness of guidelines needs to be promoted for better management of chronic urticaria.

Keywords: Chronic urticaria; Guidelines; Latin America; Management; Treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Rates of searching for csU etiology according to specialty among physicians who know the EAACI/GA2LEN/EDF/WAO guidelines, in percentage. b Rates of searching for csU etiology according to specialty among physicians who don’t know the EAACI/GA2LEN/EDF/WAO guidelines, in percentage

References

    1. Zuberbier T, Aberer W, Asero R, Bindslev‐Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–87. doi: 10.1111/all.12313. - DOI - PubMed
    1. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy. 2011;66(3):317–30. doi: 10.1111/j.1398-9995.2010.02496.x. - DOI - PubMed
    1. DeLong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35–9. doi: 10.1001/archdermatol.2007.5. - DOI - PubMed
    1. Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. doi: 10.1111/j.1365-2230.1994.tb01167.x. - DOI - PubMed
    1. Beck LA, Bernstein JA, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017;97(2):149–58. doi: 10.2340/00015555-2496. - DOI - PubMed